Kintara Therapeutics Inc (NASDAQ:KTRA) has announced the appointment of corporate finance veteran Tamara Seymour to its board of directors.
Seymour replaces John Liatos, who will continue in his role as Kintara's senior vice president of business development, the company noted.
"We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," Kintara CEO Saiid Zarrabian said in a statement.
READ: Kintara Therapeutics says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option for GBM patients
"Tamara's insights and perspectives will be a valuable addition to the Board and the entire Company as we continue to advance our platform assets VAL-083 and REM-001. We wish to thank John for his service to the Board and are excited to continue working with him as the Company's Senior VP of Business Development," Zarrabian added.
Kintara noted that Seymour has three decades of experience in the biotech and life sciences industries, including 20 years as a chief financial officer. Her experience includes leading finance, investor relations, managed care and reimbursement, human resources, administration, and information technology.
She has raised over $250 million in multiple private and public equity and debt financings, including spearheading an IPO. She is a member of the board and audit committee of Artelo Biosciences Inc (NASDAQ:ARTL), a clinical-stage biopharmaceutical company in California, and a former CFO at multiple private and public companies where she played an integral role in merger and acquisition activities.
Her most recent CFO posts included serving as Interim CFO of Immunic Inc (NASDAQ:IMUX), a clinical-stage drug development company where she was instrumental in its transition from being a venture-backed private entity to a publicly-traded, post-merger company with Vital Therapies Inc.
Seymour has also served as CFO of molecular diagnostics company Signal Genetics Inc and CFO of Favrille Inc, a clinical-stage drug development company.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham